Quick Answer
OCULAR THERAPEUTIX, INC reported Operating Income Loss of -$270.02 million for the year ending 2025.
- OCULAR THERAPEUTIX, INC showed a decrease of -57.2% in Operating Income Loss from 2024 to 2025.
- This data is from OCULAR THERAPEUTIX, INC's annual report (Form 10-K), filed with the SEC on February 5, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: -$3.42 million | Q1 2014: -$6.83 million | Q2 2014: -$5.95 million | Q3 2014: -$6.78 million | Q4 2014: -$7.55 million | Q1 2015: -$7.11 million | Q2 2015: -$9.64 million | Q3 2015: -$11.17 million | Q4 2015: -$10.28 million | Q1 2016: -$10.51 million | Q2 2016: -$11.11 million | Q3 2016: -$9.24 million | Q4 2016: -$12.47 million | Q1 2017: -$15.67 million | Q2 2017: -$18.34 million | Q3 2017: -$15.20 million | Q4 2017: -$12.72 million | Q1 2018: -$13.46 million | Q2 2018: -$13.56 million | Q3 2018: -$14.82 million | Q4 2018: -$17.28 million | Q1 2019: -$19.66 million | Q2 2019: -$21.60 million | Q3 2019: -$23.14 million | Q4 2019: -$21.40 million | Q1 2020: -$16.61 million | Q2 2020: -$17.88 million | Q3 2020: -$14.01 million | Q1 2021: -$20.23 million | Q2 2021: -$20.23 million | Q3 2021: -$19.53 million | Q1 2022: -$17.83 million | Q2 2022: -$19.92 million | Q3 2022: -$21.54 million | Q1 2023: -$22.55 million | Q2 2023: -$20.57 million | Q3 2023: -$19.21 million | Q1 2024: -$31.62 million | Q2 2024: -$43.59 million | Q3 2024: -$46.00 million | Q1 2025: -$63.92 million | Q2 2025: -$67.64 million | Q3 2025: -$68.70 million.
- Over the full 14 years of available data (2012 to 2025), OCULAR THERAPEUTIX, INC's Operating Income Loss has declined by 1,875.1%.
- Historical annual values: Fiscal year 2025: -$270.02 million | Fiscal year 2024: -$171.78 million | Fiscal year 2023: -$82.38 million | Fiscal year 2022: -$78.65 million | Fiscal year 2021: -$78.04 million | Fiscal year 2020: -$62.85 million | Fiscal year 2019: -$85.80 million | Fiscal year 2018: -$59.12 million | Fiscal year 2017: -$61.92 million | Fiscal year 2016: -$43.33 million | Fiscal year 2015: -$38.20 million | Fiscal year 2014: -$27.09 million | Fiscal year 2013: -$12.90 million | Fiscal year 2012: -$13.67 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: